CENTRAL NEURAL CONTROL OF GASTRIC MUCOSAL DEFENSE
胃粘膜防御的中枢神经控制
基本信息
- 批准号:2518274
- 负责人:
- 金额:$ 19.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1987
- 资助国家:美国
- 起止时间:1987-01-01 至 1999-08-31
- 项目状态:已结题
- 来源:
- 关键词:3,4 dihydroxyphenylacetate dopamine agonists dopamine antagonists dopamine receptor gastric acid gastric mucosa gastrins gastrointestinal epithelium hormone regulation /control mechanism hypothermia laboratory rat messenger RNA neuroregulation neurotensin norepinephrine nucleus accumbens polymerase chain reaction prostaglandins receptor expression secretion tegmentum vagotomy vagus nerve
项目摘要
Administration of neurotensin (NT) into the dopamine (DA)-containing
nuclei of the mesolimbic system; nucleus accumbens (NACB) and ventral
tegmental area (VTA); in the brain inhibits gastric acid secretion and
affords gastric mucosal protection against cold water restraint (CWR)
induced gastric mucosal injury. The unifying hypothesis is that CWR-
induced hypothermia reduces NT activity in the mesolimbic system by
reducing NT message, causing a reduction of dopamine activity and a
reduction in alpha and beta adrenergic activity in these nuclei resulting
in either increased vagal tone or decreased sympathetic tone which will
then result in increased rates of gastric acid secretion or reduced
endogenous mucosal prostaglandin synthesis. The proposed studies will
better define l) the effect of CWR on mesolimbic levels of NT, DA, and NT
mRNA and the B-max and K-D for NT and DA receptors; 2) the role played by
central adrenergic and dopaminergic receptor activation; and 3) the
mechanism(s) by which NT enhances gastric mucosal prostaglandin activity.
Concentrations of mesolimbic NT, DA, and NT mRNA, and NT and DA receptor
number (B-max) and affinity (K-D) will be measured at various time
intervals (15-120 min) during CWR and following the stereotaxic
administration of a NT, DA or specific receptor antagonists into the NACB
or VTA. These studies will provide information regarding the role of NT in
the mesolimbic nuclei during CWR and control of NT and DA receptor
activity during CWR. Central (mesolimbic) or systemic pretreatment with
alpha1, alpha2, beta1, beta2, DA1, or DA2 receptor agonists, antagonists,
and truncal vagotomy before 1) central NT administration followed by CWR;
or 2) pentagastrin administration will provide information regarding the
role of central adrenergic and dopaminergic mediation of antisecretory and
protective effects of central NT. The effect of specific pharmacological
dopaminergic, adrenergic, and truncal vagotomy preceding central NT
administration, on gastric mucosal prostaglandin generation will provide
information regarding the potential mechanism(s) by which central NT
enhances gastric mucosal prostaglandin generation. These studies will
enhance our understanding of central control of gastric mucosal function
and may provide new avenues through which mucosal defense mechanisms can
be enhanced.
给药神经紧张素(NT)进入含多巴胺(DA)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GORDON L KAUFFMAN其他文献
GORDON L KAUFFMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GORDON L KAUFFMAN', 18)}}的其他基金
CENTRAL NEURAL CONTROL OF GASTRIC MUCOSAL DEFENSE
胃粘膜防御的中枢神经控制
- 批准号:
2140315 - 财政年份:1987
- 资助金额:
$ 19.22万 - 项目类别:
CENTRAL NEURAL CONTROL OF GASTRIC MUCOSAL DEFENSE
胃粘膜防御的中枢神经控制
- 批准号:
3237462 - 财政年份:1987
- 资助金额:
$ 19.22万 - 项目类别:
CENTRAL NEURAL CONTROL OF GASTRIC MUCOSAL DEFENSE
胃粘膜防御的中枢神经控制
- 批准号:
2770371 - 财政年份:1987
- 资助金额:
$ 19.22万 - 项目类别:
CENTRAL NEURAL CONTROL OF GASTRIC MUCOSAL DEFENSE
胃粘膜防御的中枢神经控制
- 批准号:
3237457 - 财政年份:1987
- 资助金额:
$ 19.22万 - 项目类别:
CENTRAL NEURAL CONTROL OF GASTRIC MUCOSAL DEFENSE
胃粘膜防御的中枢神经控制
- 批准号:
2140316 - 财政年份:1987
- 资助金额:
$ 19.22万 - 项目类别:
CENTRAL NEURAL CONTROL OF GASTRIC MUCOSAL DEFENSE
胃粘膜防御的中枢神经控制
- 批准号:
3237463 - 财政年份:1987
- 资助金额:
$ 19.22万 - 项目类别:
CARDIOVASCULAR DETERMINANTS OF CATECHOLAMINE RELEASE
儿茶酚胺释放的心血管决定因素
- 批准号:
3335719 - 财政年份:1977
- 资助金额:
$ 19.22万 - 项目类别:
PROSTAGLANDIN ACTIVITY AND CONTROL OF GASTRIC MUCOSAL BLOOD FLOW
前列腺素活性和胃粘膜血流控制
- 批准号:
4689064 - 财政年份:
- 资助金额:
$ 19.22万 - 项目类别:
相似海外基金
EFFECT OF DOPAMINE AGONISTS ON PLASMA AMINO ACIDS
多巴胺激动剂对血浆氨基酸的影响
- 批准号:
7203395 - 财政年份:2005
- 资助金额:
$ 19.22万 - 项目类别:
DOPAMINE AGONISTS AS INHIBITORS OF PROLACTIN SYNTHESIS
多巴胺激动剂作为催乳素合成抑制剂
- 批准号:
7180899 - 财政年份:2005
- 资助金额:
$ 19.22万 - 项目类别:
DOPAMINE AGONISTS AS INHIBITORS OF PROLACTIN SYNTHESIS
多巴胺激动剂作为催乳素合成抑制剂
- 批准号:
6976586 - 财政年份:2004
- 资助金额:
$ 19.22万 - 项目类别:
Inhaled dopamine agonists for late stage Parkinsonism
吸入多巴胺激动剂治疗晚期帕金森病
- 批准号:
6792448 - 财政年份:2003
- 资助金额:
$ 19.22万 - 项目类别:
Inhaled dopamine agonists for late stage Parkinsonism
吸入多巴胺激动剂治疗晚期帕金森病
- 批准号:
6914942 - 财政年份:2003
- 资助金额:
$ 19.22万 - 项目类别:
DOPAMINE AGONISTS FOR THE THERAPY OF COCAINE ADDICTION
多巴胺激动剂治疗可卡因成瘾
- 批准号:
6379037 - 财政年份:2000
- 资助金额:
$ 19.22万 - 项目类别:
DOPAMINE AGONISTS FOR THE THERAPY OF COCAINE ADDICTION
多巴胺激动剂治疗可卡因成瘾
- 批准号:
6310834 - 财政年份:2000
- 资助金额:
$ 19.22万 - 项目类别:
DOPAMINE AGONISTS AS INHIBITORS OF PROLACTIN SYNTHESIS
多巴胺激动剂作为催乳素合成抑制剂
- 批准号:
6120219 - 财政年份:1999
- 资助金额:
$ 19.22万 - 项目类别:
DOPAMINE AGONISTS FOR THE THERAPY OF COCAINE ADDICTION
多巴胺激动剂治疗可卡因成瘾
- 批准号:
6016930 - 财政年份:1999
- 资助金额:
$ 19.22万 - 项目类别: